Evidence map›Paper›PMID 40163299›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

A Robust siRNA Screening Approach with Optimized Conditions for Large-Scale Transfection in Multiple Human Cancer Cell Lines.

Fabio Gasparri, Ivan Fraietta, Laura Gianellini, Marisa Montemartini, Laura Raddrizzani, Alessio Somaschini, Giorgio Ukmar, Riccardo Colombo, Claudia Perrera

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fabio GasparriNerviano Medical Sciences Srl, Nerviano, Milan, Italy. fabio.gasparri@nervianoms.com.
Ivan FraiettaNerviano Medical Sciences Srl, Nerviano, Milan, Italy.
Laura GianelliniNerviano Medical Sciences Srl, Nerviano, Milan, Italy.
Marisa MontemartiniNerviano Medical Sciences Srl, Nerviano, Milan, Italy.
Laura RaddrizzaniNerviano Medical Sciences Srl, Nerviano, Milan, Italy.
Alessio SomaschiniNerviano Medical Sciences Srl, Nerviano, Milan, Italy.
Giorgio UkmarNerviano Medical Sciences Srl, Nerviano, Milan, Italy.
Riccardo ColomboNerviano Medical Sciences Srl, Nerviano, Milan, Italy.
Claudia PerreraNerviano Medical Sciences Srl, Nerviano, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During the past decades, advances in RNA interference (RNAi) technology have paved the way for the systematic exploration of gene function, and phenotypic screening of small interfering RNA (siRNA) oligonucleotides is a strategy still commonly pursued for the identification and validation of targets, particularly in oncology drug discovery. Here we present a method for large-scale automated siRNA transfection and cell phenotypic screening using colony formation as a readout. Experimental conditions were optimized to achieve efficient and nontoxic transfection of siRNA oligonucleotides in different cell lines using liposomal reagents. For each gene, the most active and specific siRNA oligos were selected through a phenotypic prescreening in HeLa cells, selected as control cell line, and grouped in the same oligo pool. Cells were then transfected at low seeding density in 96-well plates, and after 7-14 days colony formation was analyzed. We have found this procedure to be more sensitive than standard 48-72 h proliferation assays for identifying genes essential for cell viability/proliferation, as it allows to reveal long-term consequences in slow growing cell lines, or phenotypes that occur after multiple cell divisions. This approach generated robust and reliable results through the limitation of siRNA off-target toxic effects by combining a pool of different siRNA oligos designed against the same target. Furthermore, a parallel evaluation of gene silencing phenotypes is performed against a large panel of cell lines, allowing the simultaneous identification of target related genetic dependencies in several cancer cell line models of different tumor origin.

Indexed as

NeoplasmsRNA, Small InterferingTransfectionCell Line, TumorCell ProliferationCell SurvivalHeLa CellsHumansRNA InterferenceRNA, Small InterferingColony formation assay (CFA)High-throughputLaboratory automationsiRNA librarysiRNA screeningTarget discovery

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.